EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Evaluation of NUN-004, a Novel Engineered Ephrin Antagonist, in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis: A Phase I/Ib, Open-Label, Escalating Dose and Extended Access Study

Michael Gerometta, Robert D Henderson, Richard Friend, Leanne T Cooper, Jing Zhao, Andrew W Boyd, Perry F Bartlett

Clinical Drug Investigation · 2025

DOI: 10.1007/s40261-024-01410-x ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Drug Investigation, 2025. Verfasst von Michael Gerometta und 6 weiteren Autor:innen. Beteiligte Einrichtung: Queensland Brain Institute, University of Queensland, St Lucia, Brisbane, QLD, 4072, Australia. mike@biosensisconsulting.com. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Receptor, EphA4, Recombinant Fusion Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: NuNerve Pty Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisReceptor, EphA4Recombinant Fusion ProteinsHumansMaleFemaleMiddle AgedAdultDose-Response Relationship, DrugAgedHealthy VolunteersHalf-LifeYoung Adult

Substanzen

Receptor, EphA4Recombinant Fusion Proteins

Autor:innen und Institutionen

  • Queensland Brain Institute, University of Queensland, St Lucia, Brisbane, QLD, 4072, Australia. mike@biosensisconsulting.com.
  • UQ Centre for Clinical Research, Royal Brisbane and Women's Hospital Campus, Herston, QLD, 4029, Australia.
  • Nucleus Network, Clive Berghofer Cancer Research Centre, Herston, QLD, 4006, Australia.
  • Queensland Brain Institute, University of Queensland, St Lucia, Brisbane, QLD, 4072, Australia.
  • School of Medicine, University of Queensland, St Lucia, Brisbane, QLD, 4072, Australia.

Förderung

  • NuNerve Pty Ltd

Zitieren

APA

Gerometta, M., Henderson, R. D., Friend, R., Cooper, L. T., Zhao, J., Boyd, A. W., & Bartlett, P. F. (2025). Evaluation of NUN-004, a Novel Engineered Ephrin Antagonist, in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis: A Phase I/Ib, Open-Label, Escalating Dose and Extended Access Study. Clinical Drug Investigation. https://doi.org/10.1007/s40261-024-01410-x

Vancouver

Gerometta M, Henderson RD, Friend R, Cooper LT, Zhao J, Boyd AW, et al. Evaluation of NUN-004, a Novel Engineered Ephrin Antagonist, in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis: A Phase I/Ib, Open-Label, Escalating Dose and Extended Access Study. Clinical Drug Investigation. 2025. doi:10.1007/s40261-024-01410-x

BibTeX
@article{Gerometta2025,
  author = {Gerometta, Michael and Henderson, Robert D and Friend, Richard and Cooper, Leanne T and Zhao, Jing and Boyd, Andrew W and Bartlett, Perry F},
  title = {Evaluation of NUN-004, a Novel Engineered Ephrin Antagonist, in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis: A Phase I/Ib, Open-Label, Escalating Dose and Extended Access Study},
  journal = {Clinical Drug Investigation},
  year = {2025},
  doi = {10.1007/s40261-024-01410-x}
}
Kostenlos starten →